An analysis of human papillomavirus testing and endocervical component on pap tests: A pilot study using the Roche Cobas®assay

2016 ◽  
Vol 44 (4) ◽  
pp. 280-282
Author(s):  
Kirsten J. Pierce ◽  
Heather S. Currens ◽  
Laura J. Tafe ◽  
Gregory J. Tsongalis ◽  
Vijayalakshmi Padmanabhan
Keyword(s):  
Human Papillomavirus ◽  
Pilot Study ◽  
Pap Tests ◽  
Human Papillomavirus Testing ◽  
Roche Cobas

A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing

2015 ◽  
Vol 69 ◽  
pp. 210-213 ◽  
Author(s):  
Farhana Sultana ◽  
Dorota M. Gertig ◽  
C. David Wrede ◽  
Dallas R. English ◽  
Julie A. Simpson ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Pilot Study ◽  
Sample Collection ◽  
Standard Practice ◽  
Cervical Sample ◽  
Human Papillomavirus Testing

scholarly journals Human Papillomavirus Testing and Reporting Rates in 2012: Results of a College of American Pathologists National Survey

2014 ◽  
Vol 139 (6) ◽  
pp. 757-761 ◽  
Author(s):  
Chengquan Zhao ◽  
Ann T. Moriarty ◽  
Mohiedean Ghofrani ◽  
Mujtaba Husain ◽  
Rosemary H. Tambouret ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Proficiency Testing ◽  
Hpv Testing ◽  
Papanicolaou Test ◽  
Squamous Cells ◽  
Human Papillomavirus Testing ◽  
Glandular Cells ◽  
Atypical Glandular Cells ◽  
Reflex Testing ◽  
Roche Cobas

Context College of American Pathologists (CAP) surveys are used to establish national benchmarks for laboratory parameters. Objective To evaluate changes in laboratory human papillomavirus (HPV) testing patterns in laboratories incorporating HPV testing with Papanicolaou tests in 2012. Design Data were analyzed from the CAP HPV Supplemental Questionnaire distributed to 1771 laboratories participating in either CAP HPV or CAP Papanicolaou proficiency testing in 2013. Results A total of 1022 laboratories (58%) responded. There were more high-risk (HR) HPV tests performed per institution as compared to previous surveys. There were more HPV tests performed within an institution as compared to previous surveys. Hybrid Capture 2 (HC2) remains the most common method (42.4%, 239 of 564); Cervista and cobas methods are used in 37.2% (210 of 564) and 14.9% (84 of 564) of laboratories, respectively. Human papillomavirus testing is offered as a reflex test after a Papanicolaou test result of atypical squamous cells of undetermined significance (ASC-US) in 89.6% of laboratories (476 of 531); as a cotest for women aged 30 years and older in 60.3% (404 of 531); as reflex testing after atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) in 42.7% (320 of 531); and as reflex testing after atypical glandular cells (AGC) in 27.3% (145 of 531). The HPV-positive rates for ASC-US and ASC-H were similar in 2012 and 2006. Cervista (49.2%, 88 of 179) and Roche cobas (27.4%, 49 of 179) are the most common methods used for genotyping. Most laboratories use the CAP Human Papillomavirus for Cytology Program for proficiency testing. Conclusions There was an increase in annual volume of HR-HPV testing with a shift toward in-house HR-HPV testing. Genotyping volumes also increased. HC2 and Cervista are most commonly used, with an increasing volume of Roche cobas testing. The most common indication for HPV testing among all laboratories was ASC-US reflex testing, but an increase in HPV cotesting was observed. The data provide an update into persisting and newer trends in HPV testing practices.

scholarly journals Cervical human papillomavirus testing to triage borderline abnormal pap tests in HIV-coinfected women

AIDS ◽  
2014 ◽  
Vol 28 (11) ◽  
pp. 1696-1698 ◽  
Author(s):  
Gypsyamber DʼSouza ◽  
Robert D. Burk ◽  
Joel M. Palefsky ◽  
L.S. Massad ◽  
Howard D. Strickler
Keyword(s):  
Human Papillomavirus ◽  
Pap Tests ◽  
Human Papillomavirus Testing ◽  
Abnormal Pap Tests ◽  
Cervical Human Papillomavirus

A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes

2016 ◽  
Vol 140 (2) ◽  
pp. 153-157 ◽  
Author(s):  
Angelique W. Levi ◽  
Jane I. Bernstein ◽  
Pei Hui ◽  
Kara Duch ◽  
Kevin Schofield ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Linear Array ◽  
The United States ◽  
Hybrid Capture ◽  
Human Papillomavirus Testing ◽  
Significant Difference ◽  
Hybrid Capture 2 ◽  
Papillomavirus Dna ◽  
Roche Cobas

Context All Food and Drug Administration–approved methods in the United States for human papillomavirus testing including the Hybrid Capture 2 human papillomavirus assay and the Roche cobas human papillomavirus test are approved for cytology specimens collected into ThinPrep media but not for specimens collected into SurePath solution. Objective To compare the performance of the Roche cobas and Hybrid Capture 2 tests for the detection of high-risk human papillomavirus using both ThinPrep and SurePath preparations as part of a validation study. Design One thousand three hundred seventy-one liquid-based cytology samples, including 1122 SurePath and 249 ThinPrep specimens, were tested for high-risk human papillomavirus DNA using the Roche cobas human papillomavirus test and the Hybrid Capture 2 human papillomavirus assay. For cases with discrepant results, confirmatory testing was performed using Linear Array human papillomavirus testing. Results One hundred and fifty-six (11.38%) and 184 (13.42%) of the 1371 specimens tested positive for high-risk human papillomavirus DNA using the Hybrid Capture 2 human papillomavirus assay and Roche cobas human papillomavirus assay, respectively. In addition, 1289 (94.0%) of 1371 specimens demonstrated concordant high-risk human papillomavirus results with a κ value of 0.72 (95% confidence interval, 065–0.78). There was no statistically significant difference in the percentage of positive high-risk human papillomavirus results between the 2 liquid-based preparations with either assay. Discordant results between the 2 assays were noted in 82 of 1371 cases (6%). Twenty-seven of 82 cases (32.9%) were Hybrid Capture 2 positive/Roche cobas negative and 55 of 82 cases (67.1%) were Roche cobas positive/Hybrid Capture 2 negative. Two of 20 Hybrid Capture 2–positive/Roche cobas–negative cases (10%) and 26 of 37 Roche cobas–positive/Hybrid Capture 2–negative cases (70%) tested positive for high-risk human papillomavirus by Linear Array. Conclusions Both assays showed good agreement and excellent specificity with either ThinPrep or SurePath preparations. The number of discordant results was relatively small. The performance of both assays was similar for ThinPrep specimens, but the Roche cobas test demonstrated higher sensitivity with SurePath specimens.

Sign in / Sign up

Export Citation Format

Share Document